Susini et al., 2021 - Google Patents
Immunohistochemical evaluation of FGD3 expression: A new strong prognostic factor in invasive breast cancerSusini et al., 2021
View HTML- Document ID
- 6966632130581784993
- Author
- Susini T
- Saccardin G
- Renda I
- Giani M
- Tartarotti E
- Nori J
- Vanzi E
- Pasqualini E
- Bianchi S
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary Breast cancer is the most incident malignancy and the leading cause of oncological death among women. The recent advances in the treatment of this disease are due to the increasing ability to individualize therapy, in the so called “precision medicine” …
- 230000014509 gene expression 0 title abstract description 175
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raffenne et al. | hENT1 testing in pancreatic ductal adenocarcinoma: are we ready? a multimodal evaluation of hENT1 status | |
| Lacombe et al. | Biomarkers of response to etoposide-platinum chemotherapy in patients with grade 3 neuroendocrine neoplasms | |
| Gentry-Maharaj et al. | Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women | |
| Palleschi et al. | Ki67 and PR in patients treated with CDK4/6 inhibitors: a real-world experience | |
| Hwang et al. | Influence of androgen receptor on the prognosis of breast cancer | |
| Chahoud et al. | Prognostic significance of p16 and its relationship with human papillomavirus status in patients with penile squamous cell carcinoma: results of 5 years follow-up | |
| Idel et al. | EVI1 as a Marker for Lymph Node Metastasis in HNSCC | |
| Kemi et al. | Immune cell infiltrate and prognosis in gastric cancer | |
| Fülöp et al. | Prognostic impact of the neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratio, in patients with rectal Cancer: a retrospective study of 1052 patients | |
| Susini et al. | Immunohistochemical evaluation of FGD3 expression: A new strong prognostic factor in invasive breast cancer | |
| Cass et al. | Automated quantitative analysis of p53, Cyclin D1, Ki67 and pERK expression in breast carcinoma does not differ from expert pathologist scoring and correlates with clinico-pathological characteristics | |
| Erber et al. | Reproducibility of mRNA-based testing of ESR1, PGR, ERBB2, and MKI67 expression in invasive breast cancer—A Europe-Wide External Quality Assessment | |
| Erber et al. | Molecular subtyping of invasive breast cancer using a PAM50-based multigene expression test-comparison with molecular-like subtyping by tumor grade/immunohistochemistry and influence on oncologist’s decision on systemic therapy in a real-world setting | |
| Silva-Oliveira et al. | Clinical significance of ARID1A and ANXA1 in HER-2 positive breast cancer | |
| Giannoula et al. | Dynamic risk stratification for predicting treatment response in differentiated thyroid cancer | |
| Malainou et al. | Estrogen-receptor-low-positive breast cancer: Pathological and clinical perspectives | |
| Pizzimenti et al. | BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI Treatment in the Thyroid Cancer ATA Intermediate Risk Category | |
| Kang et al. | Lymph Node Ratio Predicts Recurrence in Patients with Papillary Thyroid Carcinoma with Low Lymph Node Yield | |
| Arslan et al. | Breast cancer characteristics in the population of survivors participating in the world trade center environmental health center program 2002–2019 | |
| Troiano et al. | Immunohistochemical analysis revealed a correlation between Musashi-2 and Cyclin-D1 expression in patients with oral squamous cells carcinoma | |
| López-García et al. | Low prevalence of HER2-positive breast carcinomas among screening detected breast cancers | |
| Bademler et al. | Clinical significance of serum membrane-bound mucin-2 levels in breast cancer | |
| Hahn et al. | Can molecular biomarkers help reduce the overtreatment of DCIS? | |
| Miller et al. | The prognostic and predictive value of sox2+ cell densities in patients treated for colorectal cancer | |
| Stefanovic et al. | The lack of evidence for an association between cancer biomarker conversion patterns and CTC-status in patients with metastatic breast cancer |